Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exploration of physiological and pathophysiological implications of miRNA-143 and miRNA-145 in cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interval Walking Improves Glycemic Control and Body Composition After Cancer Treatment: A Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Does inflammation have a role in migraine?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. The changing faces of migraine

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

CGRP plays a major role in the pathophysiology of migraine. Concomitant, CGRP plays a role in endogenous neurovascular protection from severe vasoconstriction associated with e.g. cerebral or cardiac ischemia. The CGRP antagonistic antibodies Fremanezumab (TEVA Pharmaceuticals) and Erenumab (Novartis/Amgen) have successfully been developed for the prevention of frequent migraine attacks. Whereas these antibodies might challenge endogenous neurovasular protection during severe cerebral or coronary vasoconstriction, potential future therapeutic CGRP agonists might induce migraine-like headaches in migraineurs. In the current study segments of cerebral artery have been used to obtain mechanistic insight of the CGRP-neutralizing anti-body Fremanezumab in neurovascular regulation in vitro. The basilar artery was selected due to its relevance in subarachnoid hemorrhage (SAH). Erenumab is known to block the human CGRP receptor and Fremanezumab to neutralize both human and rat CGRP. Results confirmed that Erenumab does not block the rat CGRP receptor and that Fremanezumab inhibits the vasodilatory effect induced by both human CGRP, rat CGRP and the metabolically stable CGRP analog, SAX in rat basilar artery. Fremanezumab also inhibits the vasodilatory effect of capsaicin in constricted segments of basilar artery. Capsaicin is used as a pharmacological tool to induce secretion of endogenous perivascular CGRP and our studies confirm that the antibody reach the perivascular sensory synaptic cleft and blocks the vasodilatory response of released CGRP in the present in vitro model. Thus, CGRP neutralization might have the mechanistic potential to block vasoprotective responses to severe vasoconstriction provided they reach the site of action and Fremanezumab is an important tool for future investigations of the impact of CGRP physiology.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Pharmacology
Vol/bind864
Sider (fra-til)172726
ISSN0014-2999
DOI
StatusUdgivet - 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 58348787